Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany

Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Krueger H, Greiner W (2015)
The European Journal of Health Economics 16(5): 471-488.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ;
Abstract / Bemerkung
In 2011, intranasally administered live attenuated influenza vaccine (LAIV) was approved in the EU for prophylaxis of seasonal influenza in 2-17-year-old children. Our objective was to estimate the potential epidemiological impact and cost-effectiveness of an LAIV-based extension of the influenza vaccination programme to healthy children in Germany. An age-structured dynamic model of influenza transmission was developed and combined with a decision-tree to evaluate different vaccination strategies in the German health care system. Model inputs were based on published literature or were derived by expert consulting using the Delphi technique. Unit costs were drawn from German sources. Under base-case assumptions, annual routine vaccination of children aged 2-17 years with LAIV assuming an uptake of 50 % would prevent, across all ages, 16 million cases of symptomatic influenza, over 600,000 cases of acute otitis media, nearly 130,000 cases of community-acquired pneumonia, nearly 1.7 million prescriptions of antibiotics and over 165,000 hospitalisations over 10 years. The discounted incremental cost-effectiveness ratio was a,not sign1,228 per quality-adjusted life year gained from a broad third-party payer perspective (including reimbursed direct costs and specific transfer payments), when compared with the current strategy of vaccinating primarily risk groups with the conventional trivalent inactivated vaccine. Inclusion of patient co-payments and indirect costs in terms of productivity losses resulted in discounted 10-year cost savings of a,not sign3.4 billion. In conclusion, adopting universal influenza immunisation of healthy children and adolescents would lead to a substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system. On the basis of the epidemiological and health economic simulation results, a recommendation of introducing annual routine influenza vaccination of children 2-17 years of age might be taken into consideration.
Erscheinungsjahr
Zeitschriftentitel
The European Journal of Health Economics
Band
16
Zeitschriftennummer
5
Seite
471-488
ISSN
PUB-ID

Zitieren

Damm O, Eichner M, Rose MA, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics. 2015;16(5):471-488.
Damm, O., Eichner, M., Rose, M. A., Knuf, M., Wutzler, P., Liese, J. G., Krueger, H., et al. (2015). Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics, 16(5), 471-488. doi:10.1007/s10198-014-0586-4
Damm, O., Eichner, M., Rose, M. A., Knuf, M., Wutzler, P., Liese, J. G., Krueger, H., and Greiner, W. (2015). Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics 16, 471-488.
Damm, O., et al., 2015. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics, 16(5), p 471-488.
O. Damm, et al., “Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany”, The European Journal of Health Economics, vol. 16, 2015, pp. 471-488.
Damm, O., Eichner, M., Rose, M.A., Knuf, M., Wutzler, P., Liese, J.G., Krueger, H., Greiner, W.: Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. The European Journal of Health Economics. 16, 471-488 (2015).
Damm, Oliver, Eichner, Martin, Rose, Markus Andreas, Knuf, Markus, Wutzler, Peter, Liese, Johannes Guenter, Krueger, Hagen, and Greiner, Wolfgang. “Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany”. The European Journal of Health Economics 16.5 (2015): 471-488.

11 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Current prospects and future challenges for nasal vaccine delivery.
Yusuf H, Kett V., Hum Vaccin Immunother 13(1), 2017
PMID: 27936348
Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model.
Gerlier L, Lamotte M, Grenèche S, Lenne X, Carrat F, Weil-Olivier C, Damm O, Schwehm M, Eichner M., Appl Health Econ Health Policy 15(2), 2017
PMID: 27943165
Direct and indirect effects of influenza vaccination.
Eichner M, Schwehm M, Eichner L, Gerlier L., BMC Infect Dis 17(1), 2017
PMID: 28441935
Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.
Shim E, Brown ST, DePasse J, Nowalk MP, Raviotta JM, Smith KJ, Zimmerman RK., Am J Prev Med 51(3), 2016
PMID: 27079638
Recent Developments in Pediatric Community-Acquired Pneumonia.
McCulloh RJ, Patel K., Curr Infect Dis Rep 18(5), 2016
PMID: 26960931
Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
Gerlier L, Lamotte M, Dos Santos Mendes S, Damm O, Schwehm M, Eichner M., Paediatr Drugs 18(4), 2016
PMID: 27272706
A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E., Infect Dis Ther 4(4), 2015
PMID: 26350238

89 References

Daten bereitgestellt von Europe PubMed Central.

Cost-effectiveness of influenza vaccination in high-risk children in Argentina.
Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC., Vaccine 19(30), 2001
PMID: 11457546
An economic analysis of annual influenza vaccination of children.
Meltzer MI, Neuzil KM, Griffin MR, Fukuda K., Vaccine 23(8), 2005
PMID: 15620473
Potential cost savings attributable to influenza vaccination of school-aged children.
White T, Lavoie S, Nettleman MD., Pediatrics 103(6), 1999
PMID: 10353970
Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age.
Marchetti M, Kuhnel UM, Colombo GL, Esposito S, Principi N., Hum Vaccin 3(1), 2007
PMID: 17245134
Cost-effectiveness of influenza vaccination of healthy children.
Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T., Vaccine 24(23), 2006
PMID: 16678945
Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada.
Skowronski DM, Woolcott JC, Tweed SA, Brunham RC, Marra F., Vaccine 24(19), 2006
PMID: 16423432
Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ., Vaccine 26(23), 2008
PMID: 18462851
Health benefits, risks, and cost-effectiveness of influenza vaccination of children.
Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA., Emerging Infect. Dis. 12(10), 2006
PMID: 17176570
Economic impact of influenza vaccination in preschool children.
Cohen GM, Nettleman MD., Pediatrics 106(5), 2000
PMID: 11061762
Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.
Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crepey P., Hum Vaccin Immunother 8(3), 2012
PMID: 22330959
Population-wide benefits of routine vaccination of children against influenza.
Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G., Vaccine 23(10), 2005
PMID: 15652671
Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.
Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, Belongia E, Zangwill KM, Mullooly J, Nordin J, Marcy SM, DeStefano F., Pediatrics 118(5), 2006
PMID: 17079576

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 24859492
PubMed | Europe PMC

Suchen in

Google Scholar